 AIM ImmunoTech Inc NYSE:AIM presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship drug Ampligen rintatolimod as a component of a Chemokine Modulatory CKM regimen for the treatment of colorectal cancer metastatic to the liver at the six-day annual meeting of the American Association for Cancer Research AACR, which kicked off on April 8, in New Orleans, Louisiana. The Ocala, Florida-based immuno-pharma company said the research was led by Roswell Park medical oncologist Sarbajit Mukherjee, in collaboration with senior investigator Pawel Kalinski, who is the chair of Iimmunology at Roswell Park. 